Short answer
Vanda Pharmaceuticals Inc. (VNDA) filed an 8-K current report with the SEC on November 20, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Vanda settled MSN’s patent challenge to generic HETLIOZ LQ oral suspension.
Vanda Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Vanda settled MSN’s patent challenge to generic HETLIOZ LQ oral suspension
- MSN licensed to launch its generic in Q1 2040, subject to earlier-entry exceptions
- Settlement preserves near-term HETLIOZ LQ exclusivity while removing litigation uncertainty
- MSN acknowledged patent validity and agreed not to challenge the licensed patents, subject to exceptions
- FTC and DOJ review required, with court dismissal and permanent injunction expected
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vanda Pharmaceuticals Inc. 8-K filings
Get the next VNDA 8-K as it lands
Follow VNDA for push alerts, or ask the research agent what this filing means.